BioNJ's C-Suite Summit is Next Friday: Topics Impacting C-Suite Decision-Making

IT'S NEXT FRIDAY - YOU NEED TO BE THERE!

Please note: BioNJ's C-Suite Summit is closed to media.

We are facing a period of discontinuous change marked by the ever-accelerating AI revolution and advancements in therapeutics ― set against the backdrop of increasing lifecycle compression (exacerbated by the Inflation Reduction Act), a tumultuous fundraising environment and growing macroeconomic uncertainty.

Join BioNJ and industry leaders on Friday, October 6, to explore the implications of these evolutions, with a focus on the trajectory of breakthrough innovation.

Check out the full-day agenda...

Registration & Networking Breakfast

Welcome & Opening Remarks

Amadou Diarra, Ph.D., Senior Vice President, Global Policy, Advocacy & Government Affairs, Bristol Myers Squibb & Chair, BioNJ
Debbie Hart, President & CEO, BioNJ

Keynote: Creating Breakthroughs

Biopharma has been on the forefront of innovation and investment for our industry, delivering 500+ therapies, ~$1T+ in acquisitions and ~1T+ in total shareholder value over the last 20 years. As investment in biopharma plateaus, questions are being raised about the future of innovation for our industry. Join us in reflecting on what the future of innovation for biopharma and beyond may look like, including new commercialization models and how portfolios are prioritized and asset development is accelerated.

Presented by:

Olivier Leclerc, Senior Partner, McKinsey & Company

Panel: State of the Industry

Industry leaders will reflect on learnings, priorities and expected evolutions across most pressing topics for the industry, including fundraising challenges, advancements in clinical innovation, the trajectory of policy reforms, the adoption and impact of ESG priorities, talent attraction and retention strategies and the state of technology breakthroughs.

Expert Panelists:

Tom Cavanaugh, Company Group Chairman, Global Commercial Strategy Organization, The Janssen Pharmaceutical Companies of Johnson & Johnson
Deborah Glasser, Head of Vaccines, NA, Sanofi
Mandeep Kaur, M.D., Senior Vice President, Global Medical Affairs and Health Outcomes Research, Horizon Therapeutics
Christine Ann Miller, President & CEO, Melinta Therapeutics
Anthony Pagano, Chief Financial Officer, Genmab

Conversation Leader:

Nisha Subramanian, Partner, McKinsey & Company

The Pace of Innovation: A Fireside Chat with Giovanni Caforio, M.D., Chair & CEO, Bristol Myers Squibb

Many life sciences companies are reassessing their pipelines and portfolio strategies in light of recent policy changes and upcoming blockbuster patent expiries. During this intimate conversation, Dr. Caforio will share his insights on the future of medical innovation and the hard choices that companies are being forced to make.

Featured Guest:

Giovanni Caforio, M.D., CEO, Bristol Myers Squibb

Conversation Leader:

Debbie Hart, President & CEO, BioNJ

Networking Break

Panel: The Next Horizon of Therapeutic Innovation and Patient and Industry Impact

New technologies are proliferating – from continued exploration in cell and gene therapy to the rise of mRNA-based platform technologies. As these therapies grow, the bar rises in terms of safety, efficacy and Patient convenience / Patient support. This talk will explore key enablers of success for innovative therapeutics in development and reimbursement, and broader implications for evolutions in the industry.

Expert Panelists:

Ronald Bartek, Co-Founder, Founding President, Friedreich’s Ataxia Research Alliance (FARA)
Ariel Berger, Executive Director, Integrated Solutions, Real-World Evidence, Evidera/PPD
Ambrose Delpino, PharmD., Head, Market Access Strategy, Oncology, Novartis
Samit Hirawat, M.D., Executive Vice President & Chief Medical Officer, Bristol Myers Squibb

Conversation Leader:

Emilio Ragosa, Managing Partner, DLA Piper

A Fireside Chat: Evolving Capital Markets

The life sciences industry market cap has more than tripled in a decade, with biotechs leading shareholder returns. However, recent macroeconomic, geopolitical and regulatory changes create new challenges. During our discussion, we'll explore the latest funding environment and implications for industry structure and raising capital.

Expert Panelists:

Michael Margolis, Senior Managing Director, Co-Head, Healthcare Investment Banking, Oppenheimer
Lynn Martin, President, NYSE Group

Conversation Leader:

Adam Lohr, Partner, Life Sciences Senior Analyst, RSM

Networking Lunch

Panel: Navigating the Complex Path Ahead for Life Sciences Financing and M&A

The life sciences industry is facing an unprecedented environment to finance innovation, overcoming regulatory uncertainties caused by the IRA and FTC lawsuits, and macro-economic slowdown with high cost of capital. On the other hand, large pharma companies need to replenish their topline by offsetting the losses due to patent expirations of their biologics pipeline. In this complex environment, the panel will discuss how to fund the innovation.

Expert Panelists:

Angus Grant, Ph.D., Executive Vice President, Business Development, Teva Pharmaceuticals
Ulrich Otte, Senior Vice President, Finance & Operations, CFO, North America, Novo Nordisk
Barbara Ryan, Board Member (Indivior, Mink Therapeutics, Safecor Health, OcuTerra and INVO Biosciences)
Eric Tokat, Co-President & Partner, Centerview Partners

Conversation Leader:

Arda Ural, Ph.D., Americas Industry Market Leader – Life Sciences & Healthcare, Ernst & Young LLP

Panel: Talent Management in Biopharma

In light of ongoing market shifts, the life sciences industry must proactively invest to shape its talent strategy of the future. This talk will explore key priorities ranging from top-talent attraction and retention with a focus on diversity, equity and inclusion to upskilling and re-skilling parts of the workforce as well as continuing to navigate a hybrid working model.

Expert Panelists:

Julie Bensignor, Senior Vice President, Human Resources, Research and Development, Bristol Myers Squibb
Jyoti Mehra, Executive Vice President, Human Resources, Gilead
Kathy Oates, CHRO US Commercial, GSK
Martin Rexroad, Chief Culture & Community Officer, PTC Therapeutics

Conversation Leader:

Binyamin Cooper, Director, Organizational Effectiveness (OE), Slalom Consulting

Panel: The Transformative Impact of Digital / AI in Biopharma

AI has begun to transform biopharma companies, from clinical development to commercial models. The next few years will likely be characterized by continued acceleration in adoption. This talk will explore potential sources of disruption and key opportunities for life sciences companies of all stages.

Expert Panelists:

Jeevan Duggempudi, Partner, AI & Analytics, IBM Consulting
Greg Meyers, Executive Vice President & Chief Digital & Technology Officer, Bristol Myers Squibb
Mark Michelet, Strategic Client Technology Director, Microsoft
Mark Pellegrino, Senior Vice President & Chief Information Officer, Insmed

Conversation Leader:

Siddhartha Bhattacharya, Partner, Technology Consulting Partner, PWC

Closing Remarks

Networking Reception

Click here to register. Registration is $695 for BioNJ Members and $895 for future BioNJ Members. BioNJ's C-Suite Summit brings together more than 200 life sciences executives ― representing a wide breadth of companies from early to late-stage, public and private and revenue and pre-revenue ― for networking and timely discussions on what's impacting C-Suite decision-making in bringing new innovation to market.

Thank You to Our Sponsors

www.BioNJ.org

This promotion was sent by BioNJ.